Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial).
Publication
, Journal Article
Chi, G; Yee, MK; Amin, AN; Goldhaber, SZ; Hernandez, AF; Hull, RD; Cohen, AT; Harrington, RA; Gibson, CM
Published in: Circulation
January 2, 2018
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Circulation
DOI
EISSN
1524-4539
Publication Date
January 2, 2018
Volume
137
Issue
1
Start / End Page
91 / 94
Location
United States
Related Subject Headings
- Venous Thromboembolism
- Treatment Outcome
- Time Factors
- Risk Factors
- Pyridines
- Patient Readmission
- Inpatients
- Humans
- Fibrinolytic Agents
- Factor Xa Inhibitors
Citation
APA
Chicago
ICMJE
MLA
NLM
Chi, G., Yee, M. K., Amin, A. N., Goldhaber, S. Z., Hernandez, A. F., Hull, R. D., … Gibson, C. M. (2018). Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial). Circulation, 137(1), 91–94. https://doi.org/10.1161/CIRCULATIONAHA.117.031187
Chi, Gerald, Megan K. Yee, Alpesh N. Amin, Samuel Z. Goldhaber, Adrian F. Hernandez, Russell D. Hull, Alexander T. Cohen, Robert A. Harrington, and C Michael Gibson. “Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial).” Circulation 137, no. 1 (January 2, 2018): 91–94. https://doi.org/10.1161/CIRCULATIONAHA.117.031187.
Chi G, Yee MK, Amin AN, Goldhaber SZ, Hernandez AF, Hull RD, et al. Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial). Circulation. 2018 Jan 2;137(1):91–4.
Chi, Gerald, et al. “Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial).” Circulation, vol. 137, no. 1, Jan. 2018, pp. 91–94. Pubmed, doi:10.1161/CIRCULATIONAHA.117.031187.
Chi G, Yee MK, Amin AN, Goldhaber SZ, Hernandez AF, Hull RD, Cohen AT, Harrington RA, Gibson CM. Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial). Circulation. 2018 Jan 2;137(1):91–94.
Published In
Circulation
DOI
EISSN
1524-4539
Publication Date
January 2, 2018
Volume
137
Issue
1
Start / End Page
91 / 94
Location
United States
Related Subject Headings
- Venous Thromboembolism
- Treatment Outcome
- Time Factors
- Risk Factors
- Pyridines
- Patient Readmission
- Inpatients
- Humans
- Fibrinolytic Agents
- Factor Xa Inhibitors